Humana Inc. (NYSE:HUM) Shares Sold by Norden Group LLC

Norden Group LLC decreased its position in shares of Humana Inc. (NYSE:HUM) by 20.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 475 shares of the insurance provider’s stock after selling 119 shares during the quarter. Norden Group LLC’s holdings in Humana were worth $217,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Kestra Private Wealth Services LLC raised its holdings in shares of Humana by 9.3% during the fourth quarter. Kestra Private Wealth Services LLC now owns 1,883 shares of the insurance provider’s stock worth $862,000 after purchasing an additional 160 shares during the last quarter. Total Wealth Planning LLC lifted its holdings in shares of Humana by 21.2% in the 4th quarter. Total Wealth Planning LLC now owns 622 shares of the insurance provider’s stock valued at $285,000 after buying an additional 109 shares during the period. Opinicus Capital Inc. purchased a new stake in shares of Humana in the fourth quarter worth about $568,000. Intact Investment Management Inc. grew its holdings in Humana by 633.3% during the fourth quarter. Intact Investment Management Inc. now owns 8,800 shares of the insurance provider’s stock worth $4,029,000 after acquiring an additional 7,600 shares during the period. Finally, Russell Investments Group Ltd. raised its position in Humana by 59.0% during the fourth quarter. Russell Investments Group Ltd. now owns 338,801 shares of the insurance provider’s stock valued at $154,948,000 after acquiring an additional 125,697 shares in the last quarter. Institutional investors and hedge funds own 92.38% of the company’s stock.

Insider Buying and Selling

In other news, Director Jorge S. Mesquita bought 545 shares of the business’s stock in a transaction on Tuesday, February 20th. The shares were bought at an average price of $367.09 per share, with a total value of $200,064.05. Following the completion of the transaction, the director now directly owns 2,578 shares in the company, valued at $946,358.02. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 0.32% of the stock is currently owned by corporate insiders.

Humana Stock Performance

NYSE HUM opened at $314.21 on Thursday. Humana Inc. has a fifty-two week low of $298.61 and a fifty-two week high of $541.21. The company has a debt-to-equity ratio of 0.77, a quick ratio of 1.67 and a current ratio of 1.67. The stock’s fifty day moving average is $325.28 and its two-hundred day moving average is $390.72. The firm has a market capitalization of $37.86 billion, a P/E ratio of 19.56, a price-to-earnings-growth ratio of 1.76 and a beta of 0.50.

Humana (NYSE:HUM) last issued its earnings results on Wednesday, April 24th. The insurance provider reported $7.23 EPS for the quarter, topping analysts’ consensus estimates of $6.12 by $1.11. The company had revenue of $29.61 billion for the quarter, compared to the consensus estimate of $28.52 billion. Humana had a net margin of 1.82% and a return on equity of 17.76%. Humana’s quarterly revenue was up 10.7% compared to the same quarter last year. During the same period in the previous year, the firm earned $9.38 earnings per share. On average, research analysts anticipate that Humana Inc. will post 16.18 earnings per share for the current year.

Humana Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, July 26th. Stockholders of record on Friday, June 28th will be issued a $0.885 dividend. The ex-dividend date of this dividend is Friday, June 28th. This represents a $3.54 annualized dividend and a dividend yield of 1.13%. Humana’s dividend payout ratio is currently 22.04%.

Analyst Ratings Changes

HUM has been the topic of a number of analyst reports. Cantor Fitzgerald dropped their price objective on shares of Humana from $391.00 to $360.00 and set a “neutral” rating on the stock in a research note on Thursday, April 25th. Royal Bank of Canada cut their price objective on shares of Humana from $415.00 to $353.00 and set an “outperform” rating for the company in a report on Thursday, April 25th. Deutsche Bank Aktiengesellschaft lowered shares of Humana from a “buy” rating to a “hold” rating and lowered their target price for the stock from $595.00 to $360.00 in a research note on Thursday, January 25th. Mizuho cut their price target on Humana from $550.00 to $400.00 and set a “buy” rating for the company in a research note on Friday, January 26th. Finally, Wells Fargo & Company cut their price objective on Humana from $413.00 to $350.00 and set an “overweight” rating for the company in a research report on Monday, April 8th. Eleven investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. According to data from MarketBeat, Humana presently has a consensus rating of “Hold” and an average target price of $424.50.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.